Search

Your search keyword '"Miyahara, Koji"' showing total 9 results
Start Over Author "Miyahara, Koji" Publisher elsevier b.v.
9 results on '"Miyahara, Koji"'

2. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Author

Akimoto, Yutaka, Nouso, Kazuhiro, Kato, Hironari, Miyahara, Koji, Dohi, Chihiro, Morimoto, Yuki, Kinugasa, Hideaki, Tomoda, Takeshi, Yamamoto, Naoki, Tsutsumi, Koichiro, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Okada, Hiroyuki, Amano, Maho, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Published
2015
Full Text
View/download PDF

3. Mo1228 ASSOCIATION OF DIRECT ORAL ANTICOAGULANT AND DELAYED BLEEDING WITH PHARMACOKINETICS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION.

Author

Sugimoto, Mitsushige, Murata, Masaki, Nagami, Yasuaki, Ominami, Masaki, Sawaya, Manabu, Nakatani, Yasuki, Furumoto, Yohei, Dohi, Osamu, Sumiyoshi, Tetsuya, Fukuzawa, Masakatsu, Kagawa, Yasuyuki, Tsuji, Shigetsugu, Miyahara, Koji, Takeuchi, Yoji, Suzuki, Sho, Tominaga, Naoyuki, Yagi, Nobuaki, Osawa, Satoshi, Sakata, Yasuhisa, and Yamada, Takanori

Published
2024
Full Text
View/download PDF

4. Association of direct oral anticoagulant and delayed bleeding with pharmacokinetics after endoscopic submucosal dissection.

Author

Murata, Masaki, Sugimoto, Mitsushige, Ueshima, Satoshi, Nagami, Yasuaki, Ominami, Masaki, Sawaya, Manabu, Nakatani, Yasuki, Furumoto, Yohei, Dohi, Osamu, Sumiyoshi, Tetsuya, Fukuzawa, Masakatsu, Tsuji, Shigetsugu, Miyahara, Koji, Takeuchi, Yoji, Suzuki, Sho, Tominaga, Naoyuki, Yagi, Nobuaki, Osawa, Satoshi, Sakata, Yasuhisa, and Yamada, Takanori

Abstract

Pharmacokinetic parameters, such as drug plasma level at trough, time to maximum plasma concentration (T max), and coagulation factor Xa (FXa) activity generally predict factors for the anticoagulant effects of direct oral anticoagulants (DOACs). Although GI bleeding is a major adverse event after endoscopic submucosal dissection (ESD), little is known about the association between post-ESD bleeding in patients taking DOACs and the pharmacologic parameters. This study aimed to evaluate pharmacologic risk factors for post-ESD bleeding in patients taking DOACs. We prospectively evaluated the incidence of post-ESD bleeding in patients taking DOACs between April 2018 and May 2022 at 21 Japanese institutions and investigated the association with post-ESD bleeding and pharmacologic factors, including plasma concentration and FXa activity at trough and T max. The incidence of post-ESD bleeding was 12.8% (14 of 109; 95% confidence interval [CI], 7.2-20.6). Although plasma DOAC concentration and plasma level/dose ratio at trough and T max varied widely among individuals, a significant correlation with plasma concentration and FXa activity was observed (apixaban: correlation coefficient, –0.893; P <.001). On multivariate analysis, risk factors for post-ESD bleeding in patients taking DOACs were higher age (odds ratio [OR], 1.192; 95% CI, 1.020-1.392; P =.027) and high anticoagulant ability analyzed by FXa activity at trough and T max (OR, 6.056; 95% CI, 1.094-33.529; P =.039). The incidence of post-ESD bleeding in patients taking DOACs was high, especially in older patients and with high anticoagulant effects of DOACs. Measurement of pharmacokinetic parameters of DOACs may be useful in identifying patients at higher risk of post-ESD bleeding. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results